Study tests stronger chemo combo for myeloma in seniors
NCT ID NCT01453088
First seen Mar 10, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study looked at two different high-dose chemotherapy treatments given before a stem cell transplant in people aged 65 and older with multiple myeloma. The goal was to see if adding the drug bortezomib to the standard chemotherapy melphalan could help keep the cancer from coming back longer. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
Conditions
Explore the condition pages connected to this study.